207 related articles for article (PubMed ID: 20630055)
1. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 3, CYP3A4 1B and MDR1 C3435T genotype distributions in Ecuadorians.
Sinués B; Vicente J; Fanlo A; Mayayo-Sinués E; González-Andrade F; Sánchez-Q D; Martínez-Jarreta B
Dis Markers; 2008; 24(6):325-31. PubMed ID: 18688081
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
4. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
6. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
8. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
Choi JH; Lee YJ; Jang SB; Lee JE; Kim KH; Park K
Br J Clin Pharmacol; 2007 Aug; 64(2):185-91. PubMed ID: 17391324
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
11. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
13. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
[TBL] [Abstract][Full Text] [Related]
15. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
17. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.
Zhao Y; Zhai D; He H; Li T; Chen X; Ji H
Eur J Clin Pharmacol; 2009 Jun; 65(6):579-84. PubMed ID: 19205682
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents.
Emich-Widera E; Likus W; Kazek B; Niemiec P; Balcerzyk A; Sieroń AL; Zak I
Biomed Res Int; 2013; 2013():526837. PubMed ID: 23984379
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
